Serious adverse events (SAEs) and non-serious adverse events (AEs)
| All patients (n = 34) | Placebo (n = 17) | Active (n = 17) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| *Data shown as number of events (event rate per patient in parentheses); †data shown as number of events and % event rate (95% confidence intervals in parentheses). | |||||||||
| SAEs* | |||||||||
| By 72 hours | 5 (0.15) | 3 (0.18) | 2 (0.12) | ||||||
| By 3 months | 10 (0.29) | 5 (0.29) | 5 (0.29) | ||||||
| AEs* | |||||||||
| By 72 hours | 23 (0.68) | 14 (0.82) | 9 (0.53) | ||||||
| By 3 months | 62 (1.82) | 31 (1.82) | 31 (1.82) | ||||||
| Death/increase in NIHSS score By ⩾4 points† | |||||||||
| By 72 hours | 5, 15% (5% to 31%) | 3, 18% (4% to 43%) | 2, 12% (1% to 36%) | ||||||
| By 3 months | 7, 21% (9% to 38%) | 4, 24% (7% to 50%) | 3, 18% (4% to 43%) | ||||||